UNSPSC 51434941: Hydrochlorothiazide/valsartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434941 Hydrochlorothiazide/valsartan is a Commodity code that encompasses branded and generic combination antihypertensive medications sold to state and local health agencies and emergency services. State and local governments purchase these medications primarily through fire and rescue services, state health and human services departments managing Medicaid or employee benefit pharmacy programs, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The actual procurement activity under this code spans emergency life support medications supplied to first responder agencies, generic pharmaceutical sourcing through multistate cooperative contracts, and state pharmacy benefit program initiatives exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include city fire departments, state health commissions, and multistate cooperative purchasing organizations; the recent opportunities show purchasing by the City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which includes participating state and local facilities.

Recent activity concentrates in Texas, Florida, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, soliciting Advanced Life Support Medications with a response deadline of April 8, 2026, for use by Tampa Fire Rescue in Hillsborough County, with an estimated contract value of $40,000 and a one-year initial term renewable for two additional one-year periods; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation, not to exceed $10,000. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with contract effectiveness July 1, 2026, and a two-year initial term. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, to gather vendor capabilities and market intelligence regarding direct-to-manufacturer prescription programs as a precursor to a formal RFP; no award value or budget range was disclosed in the RFI materials.